Meg welcomes Dr. Amy Hauck Newman, the Scientific Director and the Chief of Molecular Targets and Medications Discovery Branch and Medicinal Chemistry Sectionof the National Institute on Drug Abuse’s Intramural Research Program also known as “NIDA” IRP. It isone of the 27 institutes and centers of the National Institutes of Health (NIH) and it is dedicated to understanding the causes, consequences and treatment of substance use disorders.
On today’s show, Dr. Amy Hauck Newman discusses her work in developing novel medications to treat substance use disorders. She explains the lengthy process of drug development and the importance of intellectual property and partnerships. Dr. Newman also highlights the role of AI and machine learning in healthcare and drug design.
Amy shares her journey into chemistry and the challenges and rewards of starting and leading her own laboratory. The use of drugs like Ozempic is touched on as well as various aspects of substance use disorder and the challenges associated with its treatment. Amy talks about the challenges in treating cocaine and methamphetamine use disorder and the emotional weight of working in this field. Finally, the conversation gets into the challenges in engaging the pharmaceutical industry when it comes to fighting substance use disorders.
Podden och tillhörande omslagsbild på den här sidan tillhör The Krinsky Company. Innehållet i podden är skapat av The Krinsky Company och inte av, eller tillsammans med, Poddtoppen.